CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC

CG Oncology Inc. has successfully completed the enrollment of patients in their BOND-003 Phase 3 monotherapy study. This study aims to evaluate the effectiveness of cretostimogene grenadenorepvec as a potential treatment for high-risk non-muscle invasive bladder cancer (NMIBC) patients who do not respond to Bacillus Calmette-Guerin (BCG). The BOND-003 study has enrolled a total of 110 patients w..